Blue Horizon International does not offer or provide medical treatment or see patients within the United States. Our cellular and exosome products are investigational and are not approved by the U.S. FDA. This website is for informational and educational purposes only and is not medical advice.

Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form
slider loading
  • Slider image 0

    Advancing Regenerative Medicine Research

    Supporting scientific research and education in regenerative medicine
  • Slider image 1

    Research Driven

    testing and documenting each detail
  • Slider image 2

    Research, Education & Collaboration

    Working with academic and clinical partners to study regenerative medicine
  • Slider image 3

    Providing Access

    to quality healthcare to people in need around the world

 

BLUE HORIZON INTERNATIONAL

Blue Horizon International (BHI) is a global healthcare consulting and innovation company specializing in adult and pediatric stem cell–based therapies. Founded in 2009, BHI operates with a unique integrated model that brings together clinical care, scientific research, and philanthropy to advance responsible regenerative medicine worldwide.

Blue Horizon International collaborates with physicians, research institutions, and regulated facilities internationally, working in accordance with recognized medical, ethical, and Good Tissue Practice standards. Our activities focus on scientific research and education in regenerative medicine.

BHI’s research has been published in peer-reviewed journals indexed by PubMed Central and the U.S. National Library of Medicine, and presented at leading scientific forums, including the American Academy of Orthopaedic Surgeons and the New York Academy of Sciences.

All cellular products evaluated in BHI-supported clinical studies follow Good Tissue Practice (GTP) standards and are conducted under IRB approval and Good Clinical Practice (GCP) guidelines. In the United States, a clinical study relating to acute ischemic stroke has been registered on ClinicalTrials.gov (Identifier: NCT03735277). Registration on ClinicalTrials.gov does not indicate FDA approval, and there is no IND in effect.

In addition to cellular therapies, BHI supports scientific research and educational initiatives involving exosomes, a rapidly evolving area of regenerative medicine. Exosome-related activities referenced by BHI are investigational, are provided for scientific and educational purposes only, and are not approved by the FDA for the diagnosis, treatment, or prevention of disease. Any exosome-related research or collaboration follows applicable regulatory requirements and ethical oversight where required.

Additional Information: More detailed information about BHI’s stem cell and exosome-related therapies can be found at www.bluehorizonstemcells.com.

Research

  • Our recent research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the American Academy of Orthopedic Surgeons Annual Meeting (New Orleans, LA, 2018), Adult Stem Cells and Regenerative Medicine Conference, The New York Academy of Sciences (NY, 2019), 7th Annual German Stem Cell Network Conference (Germany, Berlin, 2019). 
  • Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
  • Our cellular and exosome products are investigational and are being studied only in research settings. They have not been shown to be safe or effective for any disease or condition and are not intended to diagnose, treat, cure, or prevent any disease.
  • A study involving human cord blood cells has been registered on ClinicalTrials.gov (Identifier: NCT03735277). Registration on ClinicalTrials.gov does not indicate FDA approval or endorsement. There is no IND in effect for our products, and our cellular products are investigational and are not approved by the FDA for any use.

Please click on the files below to learn more about our research:

A Retrospective Study to Evaluate the Safety of Cultured Human Wharton’s Jelly Mesenchymal Stem Cell Therapy provided at BHI Jamaica

A Retrospective Study to Evaluate the Safety of Cultured Human Wharton’s Jelly Mesenchymal Stem Cell Therapy provided at BHI Slovakia

BHI Umbilical Cord Blood

BHI Conditioned Media

BHI Adipose Tissue

 

 

 

About Blue Horizon International

Blue Horizon International is a healthcare-management and research organization focused on advancing scientific research and education in regenerative medicine. We collaborate with academic and clinical partners, including affiliations with university research institutions, and our affiliates operate in accordance with the applicable regulatory requirements of the jurisdictions in which they are licensed. Our cellular and exosome products are investigational and are not approved by the U.S. FDA.

The statements on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). Our cellular and exosome products are investigational, are not FDA-approved, and are not intended to diagnose, treat, cure, or prevent any disease. The information provided here is for educational purposes only and is not medical advice.

Recent News
Address
Blue Horizon International, LLC 214 State Street, Suite 101 Hackensack, NJ 07601 | USA
Get in touch with us

© 2026 Blue Horizon International, LLC. All rights reserved. This website is only intended for consumers outside the United States.